GlobalData on MSN5 天
Ractigen’s RAG-01 shows potential in treating non-muscle invasive bladder cancer
The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...
pharmaphorum5 天
MiNA’s gene-activating tech wins an AstraZeneca alliance
UK biotech MiNA Therapeutics’ RNA-based gene-activating technology has caught the eye of big pharma AstraZeneca. AZ has teamed up with the London-based startup to develop its small, activating ...
PipelineReview.com6 天
Ractigen’s RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data ...
NANTONG, China and MELBOURNE, Australia I March 24, 2025 I Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, today announced the ...
EMBO Press6 天
PARP7 as a new target for activating anti-tumor immunity in cancer
PARP7 is a mono-ADP-ribosyl transferase (mono-ART) which has recently gained attention due to its emerging role as a negative ...
来自MSN17 天
RNA molecule identified as possible driver of gastric cancer
"Since resistance to chemotherapy, immunotherapy and/or radiation is commonly observed in esophageal and gastric cancer patients," Guda said, "we will also test whether therapy resistance is ...
Yahoo Finance6 天
Ractigen's RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data ...
NANTONG, China and MELBOURNE, Australia, March 24, 2025 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics ...